Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ735MR)

This product GTTS-WQ735MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ735MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5876MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ14999MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ12451MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ10856MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ1467MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ7709MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ12724MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ10993MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW